Ketamine hydrochloride--DEA schedule III, ketamine hydrochloride--DEA schedule III and 2 more items

The University of Virginia awarded contract A207_PO-0083994-V3 to Sigma-Aldrich Inc. on August 8, 2026, with a cumulative contract value of $64. The prime contractor is supplying three distinct pharmaceutical products classified as controlled substances under the Drug Enforcement Administration (DEA) scheduling framework. The line items include Ketamine Hydrochloride (DEA Schedule III), a combination formulation of Ketamine Hydrochloride and Xylazine Hydrochloride, and Xylazine Hydrochloride. The specified quantity for Xylazine Hydrochloride is 64 units at a unit price of $1 each, with similar unit pricing applied to the other line items.

This procurement was executed by the University of Virginia, a public research institution located in Virginia. The contract deliverables are designated for delivery to the buyer, though specific performance locations or additional facility details are not specified in the available documentation. The minimal contract value relative to the volume of controlled substances being procured suggests this represents a specialized laboratory or research-focused acquisition rather than a commercial supply arrangement. No distinct contract period of performance dates beyond the award date of August 8, 2026, are provided in the source materials.